Physician profile
Patrick L George
NPI 1134126204
$5,591.06
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,320 · 2022: $2,313 · 2023: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,212.33 | 2021-2023 | Ofev, Jardiance, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $538.70 | 2021-2023 | Xarelto |
| Abbott Laboratories | $519.21 | 2021-2022 | |
| Esperion Therapeutics, INC. | $432.42 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $285.42 | 2021-2023 | Symbicort, Breztri |
| Amgen INC. | $271.98 | 2021-2023 | Repatha |
| Actelion Pharmaceuticals US, INC. | $268.50 | 2021-2023 | Uptravi |
| Glaxosmithkline, LLC. | $211.09 | 2021-2023 | Nucala |
| Impulse Dynamics (USA) INC. | $210.45 | 2022-2023 | Optimizer |
| Pfizer INC. | $182.58 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $152.68 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $147.16 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.04 | 2021-2023 | |
| Genzyme Corporation | $141.85 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $122.09 | 2021-2023 | Eliquis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $104.55 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $87.52 | 2022-2023 | Verquvo |
| Astellas Pharma US INC | $81.84 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $66.59 | 2022-2023 | Arcalyst |
| Teva Pharmaceuticals USA, INC. | $57.12 | 2021-2022 | |
| Philips North America LLC | $50.24 | 2022 | |
| Grifols USA, LLC | $48.12 | 2023 | Prolastin-C Liquid |
| Inogen, INC. | $42.42 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Daiichi Sankyo INC. | $37.62 | 2021-2023 | Injectafer |
| Irhythm Technologies, INC. | $28.35 | 2021 | |
| Boston Scientific Corporation | $23.90 | 2023 | Watchman Access System |
| Baxter Healthcare | $23.45 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $22.31 | 2021 | |
| Mylan Specialty L.P. | $22.28 | 2022 | |
| Alnylam Pharmaceuticals INC. | $21.68 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $18.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.51 | 2023 | Glassia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.